In the midst of COVID-19 pandemic striking the entire world including Indonesia throughout 2020, Tempo Scan Group at the end of the year 2020 managed to record a net profit of Rp 787 billion, rising significantly by 42.1% compared to 2019, and likewise, the EBITDA grew by 32.2% and reached Rp 1.35 trillion. The achievement of such net profit was, among others, gained from the net sales of Rp 10.97 billion contributed by the three main divisions of Tempo Scan, namely Pharmaceutical Division, Consumer Products & Cosmetics Division, and Distribution Division. In addition, Tempo Scan also succeeded in reducing its operational costs by 17.6%.

All the good results from Tempo Scan are inseparable from the support of all employees, business partners, suppliers, customers, professionals, and shareholders.